Anti-PD1-resistant MSI patients could result from tumor microenvironment of insufficient infiltration of CD8+ T-cell or tumor microenvironment of terminal exhaustion of CD8+ T cells, and treatment strategies need to be different. The gene discussed is CD8A; the disease is neoplasm.